SMITHKLINE AUGMENTIN SALES JUMP 73% IN U.S. DURING STRONG FIRST QUARTER FLU SEASON; BRISTOL PRAVACHOL SALES UP 48% TO $374 MIL., TAXOL GROWS BY 10%
Executive Summary
SmithKline Beecham's antibiotic Augmentin soared to a 73% sales increase in the U.S. during the first quarter as a strong flu season helped produce dramatic increases in sales for anti-infective products across the industry. Augmentin posted $204 mil. in sales for the quarter in the U.S. and was SB's number one product for the period. Worldwide sales reached $419 mil., a 29% increase. SB calculates its sales figures at actual average rates of exchange and uses comparable exchange rates to calculate increases.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth